Proactive Investors - Run By Investors For Investors

Bod Australia’s shares rise as it prepares to launch cannabis-based cosmetics

Planning to commercialise and distribute the products to consumers by 2018.
cannabis plant
Partnership with Swiss herbal extracts company

Bod Australia Ltd (ASX:BDA) has commenced exploratory formulation work on a new range of cannabis-based cosmetic products via its partnership with Swiss herbal extracts company Linnea SA.

Bod’s share prices has increased 70% in the past one week and is trading at $0.17 intra-day.

Pursuant to the agreement, Linnea will also assist Bod in developing cannabis-based topical treatments for inflammation and sensitive skin, including serums, foam-based creams and balms.

A key value-driver for the new cosmetic range will be the use of Linnea’s unique NioSkin™ ingredient as an active ingredient and transporter of the cannabis.

NioSkin provides superior therapeutic outcomes than standard cannabis cosmetics by efficiently enhancing skin penetration of the cannabis-based extracts.

Bod is currently conducting research and development for its cannabis-based skincare products and is planning to commercialise and distribute the products to consumers by 2018.

The products will be developed and manufactured at facilities in Italy, and exported to numerous major markets beyond Australia, including Asia and the Americas.

Discussions are underway with third-parties for white labelling and wholesale distribution.

The global skincare market is expected to reach $233.7 billion by 2022.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full BDA profile View Profile

Bod Australia Ltd Timeline

Related Articles

November 01 2018
The 35,000 sq ft automated facility is equipped with proprietary fertigation, operational and security systems
High Hampton Holdings set to add near term revenue to bottom line with Mojave Jane acquisition
November 13 2018
Mojave Jane is a California-licensed manufacturer of premium cannabis extracts and concentrates for buyers in the US state
Laboratory testing
October 10 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use